Detection of Mitochondrial Diseases pp 149-156 | Cite as
Identification of mitochondrial deficiency using principal component analysis
Chapter
Abstract
The mitochondrial pathologies are a heterogeneous group of metabolic disorders that are characterized by anomalies of oxidative phosphorylation, especially in the respiratory chain. The diagnosis of these pathologies involves many investigations among which biochemical study is at present the main tool. However, the analysis of the results obtained during such study remains complex and often does not make it possible to conclude clearly if a patient is affected or not by a biochemical and/or bioenergetic deficiency.
This arises from two main problems:
- 1.
The determination of control values from the whole set of variable values (affected and unaffected people).
- 2.
The small size of the population studied and the large number of variables collected which present a rather large variability. To cope with these problems, the principal component analysis method is applied to the results obtained during our biochemical studies. This analysis makes it possible for each respiratory chain complex, to distinguish clearly two subsets of the whole population (affected and unaffected people) as well as to detect the variables which are the most discriminative. (Mol Cell Biochem 174: 149–156, 1997)
Key words
mitochondria mitochondrial myopathies oxidative phosphorylation principal component analysis (PCA) biplotPreview
Unable to display preview. Download preview PDF.
References
- 1.Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B: Severe hypermetabolism of non-thyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical and morphological study. J Clin Invest 41: 1776–1804, 1962PubMedCrossRefGoogle Scholar
- 2.Di Mauro S, Bonilla E, Zeviani M, Walton J, De Vivo DC: Mitochondrial myopathies. Ann Neurol 17: 521–538, 1985CrossRefGoogle Scholar
- 3.Morgan-Hughes JA: Mitochondrial myopathies. In: AG Engel, BQ Banker (eds). Myology. McGraw Hill, New-York, 1986, pp 1709–1743Google Scholar
- 4.Wallace DC: Diseases of the mitochondrial DNA. Ann Rev Biochem 61: 1175–1212, 1992PubMedCrossRefGoogle Scholar
- 5.Wallace DC: Mitochondrial diseases: genotype versus phenotype. Trends Genet 9: 128–133, 1993PubMedCrossRefGoogle Scholar
- 6.Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AMS, Elsas LJ, Nikoskelaainen EK: Mitochondrial DNA mutation associated with Leber’s heredity optic neuropathy. Science 242: 1427–1430, 1988PubMedCrossRefGoogle Scholar
- 7.Lestienne P, Ponsot G: Kearns-Sayre syndrome with muscle mitochondrial DNA deletion. Lancet 1: 885, 1988PubMedCrossRefGoogle Scholar
- 8.Holt IJ, Harding AK, Morgan-Hughes JA: Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331: 717–719, 1988PubMedCrossRefGoogle Scholar
- 9.Rotig A, Colonna M, Bonnefont J-P, Blanche S, Fischer A, Saudubray J-M, Munich A: Mitochondrial DNA deletion in Pearson’s marrow-pancreas syndrome. Lancet 1: 902–903, 1989PubMedCrossRefGoogle Scholar
- 10.Shoffner JM, Lott MT, Lezza AMS, Seibel P, Ballinger SW, Wallace DC: Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation. Cell 61: 931–937, 1990PubMedCrossRefGoogle Scholar
- 11.Inui K, Fukushima H, Tsukamoto H, Taniike M, Midorikawa M, Tanaka J, Nishigaki T, Okada S: Mitochondrial encephalomyopathies with the mutation on the mitochondrial tRNALeu[UUR] gene. J Pediatrics 120:62–66, 1991CrossRefGoogle Scholar
- 12.Kobayashi Y, Momoi MY, Tominaga K, Shimoizumi H, Nihei K, Yanagisawa M, Kagawa Y, Ohta S: Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNALeu[ULJR] gene in mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Am J Hum Genet 49: 590–599, 1991PubMedGoogle Scholar
- 13.Lauber G, Marsac C, Kadenbach B, Seibel P: Mutations in mitochondrial tRNA genes: a frequent cause of neuromuscular diseases. Nucleic Acids Res 19: 1393–1397, 1991PubMedCrossRefGoogle Scholar
- 14.Noer AS, Sudoyo H, Lertrit P, Thyagarajan D, Utthanaphol P, Kapsa R, Byrne E, Marzuki S: A tRNA-Lys mutation in the mtDNA is causal genetic lesion underlying myoclonic epilepsy and ragged-red fiber (MERRF) syndrome. Am J Hum Genet 49: 715–722, 1991PubMedGoogle Scholar
- 15.Zeviani M, Amati P, Bresolin N, Antozzi C, Piccolo G, Toscano A, DiDonato S: Rapid detection of the AüG (8344) mutation of the mtDNA in Italian families with myoclonus epilepsy and ragged red fibers (MERRF). Am J Hum Genet 48: 203–211, 1991PubMedGoogle Scholar
- 16.Reardon W, Ross RJM, Sweeney MG, Luxon LM, Pembrey ME, Harding AE, Trembath RC: Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet 340: 1376–1379, 1992PubMedCrossRefGoogle Scholar
- 17.Letellier T, Malgat M, Coquet M, Mazat J-P: Mitochondrial myopathy studies on permeabilized muscle fibres. Pediatr Res 32: 17–22, 1992PubMedCrossRefGoogle Scholar
- 18.Venables WN, Ripley BD: Modern Applied Statistics with S-Plus. Springer, New York, 1994Google Scholar
- 19.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275, 1951PubMedGoogle Scholar
- 20.Srere PA: Citrate synthase. In: SP Colowick, NO Kaplan, JM Lowenstein (eds). Methods in Enzymology, New York, London, 1969, PP 3–11Google Scholar
- 21.Jolliffe IT: Principal Component Analysis. Springer, New York, 1986CrossRefGoogle Scholar
- 22.Jolliffe IT: Principal component analysis and exploratory factor analysis. Stat Meth Med Res 1: 69–95, 1992CrossRefGoogle Scholar
- 23.Durrieu G, Letellier T, Antoch J, Deshouillers JM, Diry M, Jurečková J, Malgat M, Marsac C, Mazat J-P: Mitochondrial myopathies: A statistical analysis of bioenergetical results. Euromit Congress, Paris, 1995Google Scholar
- 24.Letellier T, Malgat M, Mazat J-P: Control of oxidative phosphorylation in muscle: Application to mitochondrial myopathies. Biochim Biophys Acta 1141: 58–64, 1993PubMedCrossRefGoogle Scholar
- 25.Letellier T, Heinrich R, Malgat M, Mazat J-P: The kinetic bases of threshold effects observed in mitochondrial diseases: a systemic approach. Biochem J 302: 171–174, 1994PubMedGoogle Scholar
- 26.Taylor RW, Birch-Machin MA, Bartlett K, Lowerson SA, Turnbull DM: The control of mitochondrial oxidations by complex III in rat muscle and liver mitochondria: Implications for our understanding of mitochondrial cytopathies in man. J Biol Chem 269: 3523–3528, 1994PubMedGoogle Scholar
- 27.Singer TP, Rocca E, Kearney EB: Fumarate reductase, succinate and NADH dehydrogenase of yeast: properties and biosynthesis. In: EC Slater Flavins (ed). Flavoproteins. Elsevier, Amsterdam, London, New York, 1966, pp 391–426Google Scholar
- 28.Birch-Machin MA, Sheperd M, Warmough J, Sherratt HSA, Bartlett K, Darley Usmar VM, Milligan WA, Welch RJ, Aynsley-Green A, Turnbull DM: Fatal lactic acidosis in infancy with a defect of complex III of the respiratory chain. Pediatr Res 25: 553–559, 1989PubMedCrossRefGoogle Scholar
- 29.Fischer JC, Ruitenbeek W, Berden JA, Trijbels JMF, Veerkamp JH, Stadhouders AM, Sengers RCA, Janssen AJM: Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin Chim Acta 153: 23–36, 1985PubMedCrossRefGoogle Scholar
- 30.Wharton DC, Tzagoloff A: Cytochrome oxidase from beef heart mitochondria. In: SP Colowick, NO Kaplan (eds). Methods in Enzymology. RW Estabrook, ME Pullman, New York, London, 1967, pp 245–250Google Scholar
Copyright information
© Springer Science+Business Media Dordrecht 1997